Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.44 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.44 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.44 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.44 |
| ▸ | GMNN | O75496 | 1/20 | 0.44 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | GSR | P00390 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6949727 | 1.00 | KMT2A (0.49) | KMT2AMEN1SMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL29383650 | 1.00 | KMT2A (0.49) | KMT2AMEN1SMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL29351076 | 0.95 | ALDH1A1 (0.48) | KMT2AMEN1SMN1; SMN2TDP1ALDH1A1 | |
| SCHEMBL744307 | 0.95 | ALDH1A1 (0.48) | KMT2AMEN1SMN1; SMN2TDP1ALDH1A1 | |
| SCHEMBL6956134 | 0.91 | TDP1 (0.53) | KMT2AMEN1TDP1L3MBTL1ALDH1A1 | |
| SCHEMBL6956189 | 0.91 | TDP1 (0.53) | KMT2AMEN1TDP1L3MBTL1ALDH1A1 | |
| SCHEMBL18157025 | 0.90 | KMT2A (0.44) | KMT2AMEN1SMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL6949730 | 0.89 | MAPT (0.44) | KMT2AMEN1SMN1; SMN2TDP1ALDH1A1 | |
| SCHEMBL17263514 | 0.87 | SMN1; SMN2 (0.42) | KMT2AMEN1SMN1; SMN2TDP1ALDH1A1 | |
| SCHEMBL29684128 | 0.87 | ALDH1A1 (0.44) | KMT2AMEN1SMN1; SMN2TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1023267-B1 | PYRIDYL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CERMOL SA (CH) | 2003-09-17 | — | — | EP | claimed |
| EP-1023267-A1 | PYRIDYL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CERMOL S.A. (CH) | 2000-08-02 | — | — | EP | claimed |
| WO-1999019302-A1 | PYRIDYL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CERMOL S.A. (CH) | 1999-04-22 | — | — | WO | claimed |
| US-10265692-B2 | Ex vivo methods for predicting and confirming in vivo metabolism of pharmaceutically active compounds | EMPIRIKO CORPORATION (US) | 2019-04-23 | — | — | US | disclosed |
| US-9968574-B2 | Treatment of MCI and Alzheimer's disease | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2018-05-15 | — | — | US | disclosed |
| US-20160303553-A1 | EX VIVO METHODS FOR PREDICTING AND CONFIRMING IN VIVO METABOLISM OF PHARMACEUTICALLY ACTIVE COMPOUNDS | EMPIRIKO CORPORATION | 2016-10-20 | — | — | US | disclosed |
| US-20160303553-A1 | EX VIVO METHODS FOR PREDICTING AND CONFIRMING IN VIVO METABOLISM OF PHARMACEUTICALLY ACTIVE COMPOUNDS | EMPIRIKO CORPORATION | 2016-10-20 | — | — | US | disclosed |
| EP-2568811-A1 | TREATMENT OF MCI AND ALZHEIMER'S DISEASE | The University Of Kentucky Research Foundation (US) | 2013-03-20 | — | — | EP | disclosed |
| WO-2011142778-A1 | TREATMENT OF MCI AND ALZHEIMER'S DISEASE | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2010132671-A1 | TREATMENT OF MCI AND ALZHEIMER'S DISEASE | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292281-A1 | TREATMENT OF MCI AND ALZHEIMER'S DISEASE | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-11-18 | — | — | US | disclosed |
| EP-1023267-B1 | PYRIDYL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CERMOL SA (CH) | 2003-09-17 | — | — | EP | disclosed |
| US-6482841-B1 | Pyridyl compounds and pharmaceutical compositions containing them | CERMOL S.A. (CH) | 2002-11-19 | — | — | US | disclosed |
| EP-1159007-A1 | USE OF GALLIC ACID ESTERS TO INCREASE BIOAVAILABILITY OF ORALLY ADMINISTERED PHARMACEUTICAL COMPOUNDS | Avmax, Inc. (US) | 2001-12-05 | — | — | EP | disclosed |
| US-6180666-B1 | Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds | ANMAX, INC. | 2001-01-30 | — | — | US | disclosed |
| WO-2000051643-A1 | USE OF GALLIC ACID ESTERS TO INCREASE BIOAVAILABILITY OF ORALLY ADMINISTERED PHARMACEUTICAL COMPOUNDS | AVMAX, INC. (US) | 2000-09-08 | — | — | WO | disclosed |
| EP-1023267-A1 | PYRIDYL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CERMOL S.A. (CH) | 2000-08-02 | — | — | EP | disclosed |
| WO-1999019302-A1 | PYRIDYL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CERMOL S.A. (CH) | 1999-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303553-A1 | EX VIVO METHODS FOR PREDICTING AND CONFIRMING IN VIVO METABOLISM OF PHARMACEUTICALLY ACTIVE COMPOUNDS | CYP3A43, CYP3A4, CYP2D6 | KMT2A 4014/4885MEN1 2675/4885SMN1; SMN2 2313/4885 |
| US-10265692-B2 | Ex vivo methods for predicting and confirming in vivo metabolism of pharmaceutically active compounds | CYP3A43, CYP3A4, CYP2D6 | KMT2A 4014/4885MEN1 2675/4885SMN1; SMN2 2313/4885 |
| US-20100292281-A1 | TREATMENT OF MCI AND ALZHEIMER'S DISEASE | CHAT, CHRM2, TPO | KMT2A 2684/4885MEN1 1188/4885SMN1; SMN2 3153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.